An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial

An Tran-Duy; Marjan Ghiti Moghadam; Martijn A. H. Oude Voshaar; Harald E. Vonkeman; Annelies Boonen; Philip Clarke; Geoff McColl; Peter M. ten Klooster; T. R. Zijlstra; Willem F. Lems; N. Riyazi; E. N. Griep; J. M. W. Hazes; Robert Landewe; Hein J. Bernelot Moens; Piet L. C. M. van Riel; Mart A. F. J. van de Laar; T. L. Jansen; Dutch Natl POET Collaboration

doi:10.1002/art.40546

An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial

An Tran-Duy, Marjan Ghiti Moghadam^*, Martijn A. H. Oude Voshaar, Harald E. Vonkeman, Annelies Boonen, Philip Clarke, Geoff McColl, Peter M. ten Klooster, T. R. Zijlstra, Willem F. Lems, N. Riyazi, E. N. Griep, J. M. W. Hazes, Robert Landewe, Hein J. Bernelot Moens, Piet L. C. M. van Riel, Mart A. F. J. van de Laar, T. L. Jansen, Dutch Natl POET Collaboration

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Web of Science)

Original language	English
Pages (from-to)	1557-1564
Number of pages	8
Journal	Arthritis & Rheumatology
Volume	70
Issue number	10
DOIs	https://doi.org/10.1002/art.40546
Publication status	Published - 1 Oct 2018

Keywords

COST-EFFECTIVENESS ANALYSIS
MODIFYING ANTIRHEUMATIC DRUGS
EULAR RECOMMENDATIONS
BIOLOGIC AGENTS
DISCONTINUATION
THERAPY
MANAGEMENT
BOOTSTRAP
UPDATE

Access to Document

10.1002/art.40546

Cite this

Tran-Duy, A., Ghiti Moghadam, M., Voshaar, M. A. H. O., Vonkeman, H. E., Boonen, A., Clarke, P., McColl, G., ten Klooster, P. M., Zijlstra, T. R., Lems, W. F., Riyazi, N., Griep, E. N., Hazes, J. M. W., Landewe, R., Bernelot Moens, H. J., van Riel, P. L. C. M., van de Laar, M. A. F. J., Jansen, T. L., & Dutch Natl POET Collaboration (2018). An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial. Arthritis & Rheumatology, 70(10), 1557-1564. https://doi.org/10.1002/art.40546

Tran-Duy, An ; Ghiti Moghadam, Marjan ; Voshaar, Martijn A. H. Oude ; Vonkeman, Harald E. ; Boonen, Annelies ; Clarke, Philip ; McColl, Geoff ; ten Klooster, Peter M. ; Zijlstra, T. R. ; Lems, Willem F. ; Riyazi, N. ; Griep, E. N. ; Hazes, J. M. W. ; Landewe, Robert ; Bernelot Moens, Hein J. ; van Riel, Piet L. C. M. ; van de Laar, Mart A. F. J. ; Jansen, T. L. ; Dutch Natl POET Collaboration. / An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial. In: Arthritis & Rheumatology. 2018 ; Vol. 70, No. 10. pp. 1557-1564.

@article{ad4d7e8bdb86418e94475baa1e677880,

title = "An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial",

keywords = "COST-EFFECTIVENESS ANALYSIS, MODIFYING ANTIRHEUMATIC DRUGS, EULAR RECOMMENDATIONS, BIOLOGIC AGENTS, DISCONTINUATION, THERAPY, MANAGEMENT, BOOTSTRAP, UPDATE",

author = "An Tran-Duy and {Ghiti Moghadam}, Marjan and Voshaar, {Martijn A. H. Oude} and Vonkeman, {Harald E.} and Annelies Boonen and Philip Clarke and Geoff McColl and {ten Klooster}, {Peter M.} and Zijlstra, {T. R.} and Lems, {Willem F.} and N. Riyazi and Griep, {E. N.} and Hazes, {J. M. W.} and Robert Landewe and {Bernelot Moens}, {Hein J.} and {van Riel}, {Piet L. C. M.} and {van de Laar}, {Mart A. F. J.} and Jansen, {T. L.} and {Dutch Natl POET Collaboration}",

year = "2018",

month = oct,

day = "1",

doi = "10.1002/art.40546",

language = "English",

volume = "70",

pages = "1557--1564",

journal = "Arthritis & Rheumatology",

issn = "2326-5191",

publisher = "Wiley",

number = "10",

}

Tran-Duy, A, Ghiti Moghadam, M, Voshaar, MAHO, Vonkeman, HE, Boonen, A, Clarke, P, McColl, G, ten Klooster, PM, Zijlstra, TR, Lems, WF, Riyazi, N, Griep, EN, Hazes, JMW, Landewe, R, Bernelot Moens, HJ, van Riel, PLCM, van de Laar, MAFJ, Jansen, TL & Dutch Natl POET Collaboration 2018, 'An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial', Arthritis & Rheumatology, vol. 70, no. 10, pp. 1557-1564. https://doi.org/10.1002/art.40546

An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial. / Tran-Duy, An; Ghiti Moghadam, Marjan; Voshaar, Martijn A. H. Oude; Vonkeman, Harald E.; Boonen, Annelies; Clarke, Philip; McColl, Geoff; ten Klooster, Peter M.; Zijlstra, T. R.; Lems, Willem F.; Riyazi, N.; Griep, E. N.; Hazes, J. M. W.; Landewe, Robert; Bernelot Moens, Hein J.; van Riel, Piet L. C. M.; van de Laar, Mart A. F. J.; Jansen, T. L.; Dutch Natl POET Collaboration.

In: Arthritis & Rheumatology, Vol. 70, No. 10, 01.10.2018, p. 1557-1564.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial

AU - Tran-Duy, An

AU - Ghiti Moghadam, Marjan

AU - Voshaar, Martijn A. H. Oude

AU - Vonkeman, Harald E.

AU - Boonen, Annelies

AU - Clarke, Philip

AU - McColl, Geoff

AU - ten Klooster, Peter M.

AU - Zijlstra, T. R.

AU - Lems, Willem F.

AU - Riyazi, N.

AU - Griep, E. N.

AU - Hazes, J. M. W.

AU - Landewe, Robert

AU - Bernelot Moens, Hein J.

AU - van Riel, Piet L. C. M.

AU - van de Laar, Mart A. F. J.

AU - Jansen, T. L.

AU - Dutch Natl POET Collaboration

PY - 2018/10/1

Y1 - 2018/10/1

KW - COST-EFFECTIVENESS ANALYSIS

KW - MODIFYING ANTIRHEUMATIC DRUGS

KW - EULAR RECOMMENDATIONS

KW - BIOLOGIC AGENTS

KW - DISCONTINUATION

KW - THERAPY

KW - MANAGEMENT

KW - BOOTSTRAP

KW - UPDATE

U2 - 10.1002/art.40546

DO - 10.1002/art.40546

M3 - Article

C2 - 29745059

VL - 70

SP - 1557

EP - 1564

JO - Arthritis & Rheumatology

JF - Arthritis & Rheumatology

SN - 2326-5191

IS - 10

ER -

Tran-Duy A, Ghiti Moghadam M, Voshaar MAHO, Vonkeman HE, Boonen A, Clarke P et al. An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial. Arthritis & Rheumatology. 2018 Oct 1;70(10):1557-1564. https://doi.org/10.1002/art.40546